Patent Application Attorney Docket No.PC10194ADAM

ereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Commissioner for Patents, Washington, D.C. 20231 on this4th day of May, 2001.

> Janice Denison (Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Lee Harland

APPLICATION NO.: 09/826,791 Examiner: To be assigned

Group Art Unit: To be assigned FILING DATE: 04/05/01

TITLE: Novel Polypeptide

Hon. Commissioner for Patents Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a).

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Respectfully submitted,

Deborah A. Martin

Attorney for Applicant(s)

Reg. No. 44,222

Pfizer Inc.

Patent Department, MS 4159 Eastern Point Road Groton, Connecticut 06340 (860) 715-1821

INFORMATION DISCLOSURE STATEMENT, 9/99, (1/2)